menu
    • menu

    Company profile for ImmunityBio

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Inducing Immunogenic Cell Death By Orchestrating the Innate (NK) and Adaptive (T Cell) Immune System. ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmunityBioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Culver City, CA 90232
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://immunitybio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/immunitybio/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ImmunityBio Receives CMA Recommendation For Anktiva
    ImmunityBio Receives CMA Recommendation For Anktiva

    12 Dec 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-12-12/immunitybio-receives-conditional-marketing-authorization-recommendation-from-the-european-medicines

    PHARMIWEB
    12 Dec 2025
    Share Share
    Survey Finds NMIBC Patients Want More Care Conversations
    Survey Finds NMIBC Patients Want More Care Conversations

    13 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251113695968/en/New-Survey-Reveals-Non-Muscle-Invasive-Bladder-Cancer-Patients-Seek-More-Care-Conversations

    BUSINESSWIRE
    13 Nov 2025
    Share Share
    ANKTIVA® Boosts Survival in Non-Small Cell Lung Cancer Patients
    ANKTIVA® Boosts Survival in Non-Small Cell Lung Cancer Patients

    08 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-08/immunitybio-s-anktiva-reverses-lymphopenia-and-extends-overall-survival-in-patients-with-advanced-n

    PHARMAWEB
    08 Sep 2025
    Share Share
    ImmunityBio Anktiva + NK Cells, Optune Gio Show 100% DCR in GBM
    ImmunityBio Anktiva + NK Cells, Optune Gio Show 100% DCR in GBM

    26 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250826147574/en/Initial-Data-Shows-100-Disease-Control-in-5-Out-of-5-Patients-With-Recurrent-Glioblastoma-With-Two-Patients-in-Near-Complete-Response-Treated-With-ImmunityBios-ANKTIVA-NK-Cell-Therapy-Plus-Optune-Gio-Device

    BUSINESSWIRE
    26 Aug 2025
    Share Share
    ImmunityBio Starts Ph 2 Of ANKTIVA In Patients With Long COVID
    ImmunityBio Starts Ph 2 Of ANKTIVA In Patients With Long COVID

    19 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250819968042/en/ImmunityBio-Announces-Phase-2-Study-of-ANKTIVA-in-Patients-with-Long-COVID

    BUSINESSWIRE
    19 Aug 2025
    Share Share
    ImmunityBio CD19 CAR-NK Shows Responses in Lymphoma Trial
    ImmunityBio CD19 CAR-NK Shows Responses in Lymphoma Trial

    13 Aug 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250813610481/en/ImmunityBio-Reports-Complete-Responses-in-Non-Hodgkin-Waldenstrom-Lymphoma-Patients-with-Chemotherapy-Free-First-In-Class-CD19-CAR-NK-Immunotherapy

    BUSINESSWIRE
    13 Aug 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search